Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Conditions: Melanoma Interventions: Drug: Ipilimumab; Drug: Nivolumab Sponsors: University of Utah Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials